These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26742881)

  • 1. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders.
    Imamura T; Kinugawa K; Nitta D; Komuro I
    Int Heart J; 2016 Sep; 57(5):593-9. PubMed ID: 27628415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan can improve clinical course in responders.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2013; 54(6):377-81. PubMed ID: 24309447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K; Doi K; Imamura T; Noiri E; Yahagi N; Nangaku M; Kinugawa K
    Nephrology (Carlton); 2015 Jun; 20(6):405-12. PubMed ID: 25619790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
    Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
    Imamura T; Kinugawa K
    Int Heart J; 2016 Sep; 57(5):600-6. PubMed ID: 27581675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
    Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K
    Clin Exp Nephrol; 2023 May; 27(5):427-434. PubMed ID: 36752971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Shiga T; Hatano M; Yao A; Kyo S; Komuro I
    Circ J; 2013; 77(5):1208-13. PubMed ID: 23318562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study.
    Imamura T; Kinugawa K; Ohtani T; Sakata Y; Higo T; Kinugawa S; Tsutsui H; Sunagawa K; Komuro I
    Int Heart J; 2014; 55(3):264-7. PubMed ID: 24806383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.